Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

A Maryland man who has lost his vision due to non-arteritic anterior ischaemic optic neuropathy (NAION) is suing Novo Nordisk ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...

A US judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and ...